UK Companies House feature
TRELLUS HEALTH PLC
Profile
- Company number
- 12743489
- Status
- Active
- Incorporation
- 2020-07-15
- Last accounts made up
- 2024-12-31
- Account category
- GROUP
- Primary SIC
- 62012
Accounts
Pending extraction
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- UK-adopted International Accounting Standards
- Reporting scope
- Consolidated (group)
- Auditor
- Crowe U.K. LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The directors believe that additional funding can be obtained to enable the Company and the Group to continue in existence for a period of at least 12 months at the date of approval of these financial statements. However, there is no guarantee that sufficient cash inflows from partnerships, equity fundraising or other sources will be forthcoming in the timeframe required. This represents a material uncertainty in relation to the funding arrangements of the Group which may result in the Company and the Group not being a going concern.”
Subsidiaries
- Trellus Health Inc · 100% held · United States of America
Significant events
- “Post-period, in January 2025, we announced a key commercial milestone: a pilot agreement with Johnson & Johnson Health Care Systems Inc. ("J&J"). This one-year collaboration will evaluate the Trellus Elevate® program's impact on supporting individuals with moderately to severely active IBD who are prescribed a J&J therapy in the U.S.”
- “During December 2024, the company received an employment tribunal claim for the underpayment of notice pay (and pension contributions), underpayment of accrues unused holiday pay, unfair dismissal, failure to provide a statement of employment terms and failure to provide a written reason for dismissal. The total sum claimed is not particularised but is subject to a statutory cap of approximately £60,000 ($75,000). The company is defending the claim and it is disputed on a number of jurisdictional and factual grounds.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
7 active · 6 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ONE ADVISORY LIMITED | Corporate Secretary | 2024-09-01 | — | — |
| DUBINSKY, Marla, Dr | Director | 2020-07-15 | Jul 1967 | American |
| ENTEL, Traci | Director | 2022-06-22 | Feb 1976 | American |
| GRIFFIN, Brian Thomas | Director | 2024-09-19 | Mar 1959 | American |
| LIUM, Erik Kristian, Dr | Director | 2020-07-15 | Mar 1968 | American |
| MURPHY, Kevin | Director | 2024-06-07 | May 1960 | American |
| SALTER, David Michael | Director | 2020-07-15 | Aug 1961 | British |
Show 6 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| HAMIR, Salim | Secretary | 2020-07-17 | 2024-09-01 |
| BAINES, Julian Huw | Director | 2020-07-15 | 2023-02-06 |
| FAYAD, Monyc Pauline | Director | 2020-07-15 | 2022-07-19 |
| GANDHI, Niyum | Director | 2020-07-15 | 2021-12-31 |
| MAHONY, Daniel, Dr | Director | 2021-03-17 | 2024-06-14 |
| MILLS, Christopher Harwood Bernard | Director | 2021-03-22 | 2024-02-28 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Ekf Diagnostics Holdings Plc | Corporate entity | Voting 25–50% | 2020-08-20 | Ceased 2020-12-18 |
| Icahn School Of Medicine At Mount Sinai | Corporate entity | Shares 25–50% | 2020-07-15 | Ceased 2020-07-15 |
Filing timeline
Last 20 of 64 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-05-07 | SH01 | capital | capital allotment shares |
| 2026-04-08 | SH01 | capital | capital allotment shares |
| 2026-03-02 | SH01 | capital | capital allotment shares |
| 2026-02-20 | PSC08 | persons-with-significant-control | notification of a person with significant control statement |
| 2026-02-20 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
| 2026-02-02 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2026-01-27 | RESOLUTIONS | resolution | resolution |
| 2025-07-17 | CS01 | confirmation-statement | confirmation statement with updates |
| 2025-07-04 | RESOLUTIONS | resolution | resolution |
| 2025-06-09 | AA | accounts | accounts with accounts type group |
| 2025-02-17 | CH01 | officers | change person director company with change date |
| 2025-02-17 | CH01 | officers | change person director company with change date |
| 2024-12-27 | AD01 | address | change registered office address company with date old address new address |
| 2024-09-19 | AP01 | officers | appoint person director company with name date |
| 2024-09-02 | TM02 | officers | termination secretary company with name termination date |
| 2024-09-02 | AP04 | officers | appoint corporate secretary company with name date |
| 2024-07-31 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-07-03 | RESOLUTIONS | resolution | resolution |
| 2024-07-01 | AA | accounts | accounts with accounts type group |
| 2024-06-29 | TM01 | officers | termination director company with name termination date |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Composite activity score · components 0–100 · reference 2026-05-09
40.8
COOL
/ 100
- Filings velocity 83
- Capital events 60
- Officer churn 0
- Headcount trajectory 50
- Accounts trajectory 50
Risk penalty: −10
- 10 filing(s) in last 12 months
- 3 capital event(s) in last 24 months
- Outstanding charges